Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Conditions
- Non-Hodgkin Lymphoma
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- Indolent B-Cell Non-Hodgkin Lymphoma
- Marginal Zone Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Interventions
- BIOLOGICAL: Mosunetuzumab
- BIOLOGICAL: Obinutuzumab
- DRUG: Polatuzumab Vedotin
- PROCEDURE: FDG-Positron Emission Tomography
- PROCEDURE: Computed Tomography
- PROCEDURE: Positron Emission Tomography
- PROCEDURE: Bone Marrow Biopsy
- PROCEDURE: Bone Marrow Aspiration
- PROCEDURE: Biospecimen Collection
Sponsor
University of Washington
Collaborators